EPISODE · May 20, 2025 · 5 MIN
BioVie CEO Cuong Do on Alzheimer’s Breakthroughs, Liver Disease Pipeline & What’s Ahead
from Small Stocks, Big Money · host RedChip Companies
BioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.BioVie is a client of RedChip. Visit RedChip.com to learn more.
What this episode covers
BioVie (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.BioVie is a client of RedChip. Visit RedChip.com to learn more.
NOW PLAYING
BioVie CEO Cuong Do on Alzheimer’s Breakthroughs, Liver Disease Pipeline & What’s Ahead
No transcript for this episode yet
Similar Episodes
Apr 29, 2025 ·12m
Apr 27, 2025 ·11m
Apr 24, 2025 ·11m
Apr 22, 2025 ·14m
Apr 22, 2025 ·32m
Feb 27, 2025 ·0m